New Zealand Confirms Amgevita Biosimilar Listing With Small Delay
Amgen’s Adalimumab Biosimilar To Replace Humira As Principal Funded Brand
Pharmac has confirmed proposals to fund Amgen’s Amgevita adalimumab biosimilar rather than the Humira reference brand from next year.
You may also be interested in...
Purchasers and payers for AbbVie’s Bystolic, formerly belonging to Forest Laboratories, have failed in their antitrust suits against a host of generic manufacturers and the originator.
Cipla has provided the latest on its US complex pipeline ahead of several potential launches in the firm’s upcoming 2022/23 financial year. The Indian firm enjoyed 6% group revenue growth in Q3 FY2022 and is on track to hit its EBITDA margin target.
After filing for Chapter 11 bankruptcy protection in October last year, Teligent has sewn up the sales of its Buena manufacturing site and ANDAs, with an auction process providing mixed results.